On May 23, 2023, Dr. Liu Muyun, Director of the National Engineering Research Center for Key Common Technologies in the Cell Industry (hereinafter referred to as the "National Engineering Center for the Cell Industry"), Qi Xuemei, Director of the General Administration Office, and Li Tongjing, Head of the Training Center, visited Shenzhen Cell Valley Biopharmaceutical Co., Ltd. for exchange. Shenzhen Cell Valley Chairman Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Assistant to the Chairman Wei Zheng, Deputy Head of R&D Sun Rui, and R&D Scientist Tan Shuxian extended a warm welcome. The two parties held symposium discussions on planned cooperation directions and specific content.

During the symposium, the two parties introduced their respective enterprises' and platforms' development strategies, core technologies, and team profiles, and explored potential directions for cooperation. The National Engineering Center for the Cell Industry and Shenzhen Cell Valley will engage in comprehensive and in-depth cooperation, closely collaborating in areas including professional talent training in the cell therapy field, establishing an automated manufacturing platform for retroviral vector-based cell therapy products, and advancing IT+BT digital and intelligent production lines for cell products. Both parties agreed to jointly establish a viral vector common technology research platform under the National Engineering Research Center for Key Common Technologies in the Cell Industry, relying on Shenzhen Cell Valley.

Both parties agreed on the need to deepen multi-dimensional cooperation, broaden cooperation areas, and achieve complementary resource advantages. In platform technologies for cell and gene therapy, both parties will pursue joint development, fully leveraging the platform's "cluster effect" to achieve China's core competitiveness in strategic industries. They will also demonstrate a exemplary effect in the integrated application of biotechnology and information technology, promoting the high-quality development of the cell industry in Shenzhen and across the country.

About the National Engineering Research Center for Key Common Technologies in the Cell Industry

      The National Engineering Research Center for Key Common Technologies in the Cell Industry is the only national-level innovation platform in China's cell industry field. It was approved to be established in Shenzhen in April 2022, led by Shenzhen Kenuo Medical Laboratory. It aims to build a key common technology supply system for China's cell and gene industry. The Center focuses on building eight major functional platforms: a novel cell and gene therapy technology R&D platform, an advanced cell intelligent manufacturing system R&D platform, a cell quality monitoring technology R&D platform, a CRO R&D laboratory, a CDMO intelligent manufacturing workshop, an industrial key materials and consumables R&D platform, a cell full-lifecycle management platform, and an industrial innovation talent training center. It also includes five major industrial facilities: a national cell bank, a pilot-scale base, an animal facility, a cold chain logistics hub, and a data storage and analysis center. According to the plan, the Center will be built into China's first national engineering research center in the cell industry that "connects basic research at universities and research institutions on one end with major market demands on the other." While committed to original R&D in cell and gene therapy, it will improve China's cell and gene therapy industry chain and supply chain and systematically enhance China's biopharmaceutical manufacturing level.